Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Immucell Corp changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 31 | 30 | −1 |
| Shares | 1.06M | 1.03M | −23.6K (−2.2%) |
| Value | $5.32M | $5.47M | +$151.2K (+2.8%) |
New holders (3)
Institutions that held Immucell Corp at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Mission Wealth Management, LP | 10,000 | $53.4K | 0.00% |
| Headinvest, LLC | 3,118 | $16.3K | 0.00% |
| JPMorgan Chase & Co | 7 | $36 | 0.00% |
Sold out (4)
Institutions that held Immucell Corp at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Empire Financial Management Company, LLC | 42,000 | $210.0K |
| Advisor Group Holdings, Inc. | 550 | $2.75K |
| Geneos Wealth Management Inc. | 244 | $1.22K |
| Coppell Advisory Solutions LLC | 141 | $698 |